Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pascal Machiels

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
Clinical Genitourinary Cancer|March 5, 2017
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?Charles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2021
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trialRachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Cancer Research|August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signalingShan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Cancer Cell|December 12, 2018
The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer PatientsMarc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
Molecular and immune landscape of recurrent and/or distant metastatic squamous cell carcinoma of the head and neck: an EORTC/IMMUCAN projectAthénaïs van der Elst, Daniel Herrero-Saboya, Lucas Michon, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
Clinical Genitourinary Cancer|March 5, 2017
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?Charles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2021
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trialRachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Cancer Research|August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signalingShan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Cancer Cell|December 12, 2018
The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer PatientsMarc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
Molecular and immune landscape of recurrent and/or distant metastatic squamous cell carcinoma of the head and neck: an EORTC/IMMUCAN projectAthénaïs van der Elst, Daniel Herrero-Saboya, Lucas Michon, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Pageof 17